Skip to content

Comparative study to evaluate the Effectiveness of GanjhuVirTM a herbal antiviral in Cases of Dengue Fever with Thrombocytopenia

An open labeled, randomized, comparative study to evaluate the Effectiveness of GanjhuVirTM a herbal antiviral in Cases of Dengue Fever with Thrombocytopenia

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017096
Enrollment
50
Registered
2019-01-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B338- Other specified viral diseases

Interventions

Intervention1: Ganjhuvir Liquid: It contains extract of Desmodium gangeticum root. 10 ml twice a day Control Intervention1: Standard Management : Standard Management of dengue like analgesics, antipyr

Sponsors

Radhika Ayurveda Research and Development
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male or Female Subject aged between 18 and 60 years 2.Diagnosis confirmed as DF Grade 1. 3.Platelet count is below 100,000 and above 30,000 per µL 4.ALT/SGPT level less than 165 U/L 5.Subject willingly giving written informed consent

Exclusion criteria

Exclusion criteria: 1.Patient diagnosed with DHF Grade 3 or 4 2.Platelet levels are less than 30,000 per µL 3.Patient is either pregnant or lactating 4.Has received blood products or blood transfusion during the current hospital stay Or during last one month 5.Is the patient diagnosed with ITP, Leukaemia or Hemophilia 6.Serum Creatinine is more than 1.4 mg/dl (if female) or 1.5mg/dl (if male) 7.Patient has participated in another trial within past one month 8.Patient with positive HIV infection 9.The investigator can exclude patient at his/her discretion depending upon the condition of the patient.

Design outcomes

Primary

MeasureTime frame
Change in mean platelet countTimepoint: Screening visit, Visit 1 Day1,Visit 2 Day3, Visit 3 Day5

Secondary

MeasureTime frame
Change in global assessment for overall improvement Percentage of participants with adverse events Changes in the vitals, Tolerability of study drugs, myalgia etc.Timepoint: Screening visit, Visit 1 Day1,Visit 2 Day3, Visit 3 Day5

Countries

India

Contacts

Public ContactDr Rajesh Ganjhu

Lokmanya medical research centre

drsdhawade@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026